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cant (p < 0.05) probability of goal attainment. Results related
to titration were equivocal. When compared to 1st and 2nd
tier statins (lovastatin, pravastatin, simvastatin, ezetimibe/
simvastatin), 3rd tier statins (n = 1171) demonstrated results
similar to atorvastatin. Condition indices were consistently <30.
Prescription data period: October 2004 to July 2006. CONCLU-
SION: Atorvastatin and 3rd tier statins were signiﬁcantly better
at achieving treatment goal in high-risk, hyperlipidemic patients.
Otherwise, atorvastatin and 3rd tier statins failed to outperform
comparators.
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OBJECTIVES: To empirically evaluate the predictive perfor-
mance and risk factor identiﬁcation of P-Course and compare it
to logistic regression (LR) using patients screened for the pres-
ence of coronary heart disease (CHD). P-Course is a web-based
naive Bayes classiﬁcation (NBC) tool which special feature is its
ability to utilize informative priors in model construction.
METHODS: 597 CHD-suspected patients underwent coronary
angiography. P-Course was compared to various forms of novel
LR approaches (full LR, backward stepwise selection using
Bayesian Information Criterion (BIC), and Bayesian Model
Averaging (BMA) with medically supported interactions). Pre-
dictive performance was measured as the proportion of cor-
rectly classiﬁed patients. The dataset was randomly split into
training and test sets. Performance was measured separately for
four different sizes of training sets (150, 200, 300, and 450).
For each size, the experiment was replicated 20 times to
improve accuracy. RESULTS: P-Course outperformed LR
approaches: the respective ranges for the average accuracies of
P-Course, full LR, stepwise BIC, and BMA with same datasets
were 0.78–0.81, 0.70–0.81, 0.70–0.80, and 0.78–0.80. In total
splits modeled (N = 3000–9000), P-Course predicted correctly
on average 63 cases more than the best comparator, BMA. The
analyses further illustrate that relevant prior information
improves P-Course’s accuracy, in particular when the training
dataset is relatively small: average accuracies with informative
and uninformative priors using training sets of sizes 25–50
were 0.70–0.71 and 0.66–0.68, respectively. In variable screen-
ing, P-Course yielded medically sensible choices of variables
regarded as the most likely risk factors for CHD. CONCLU-
SION: In addition to previous work done with P-Course (e.g.,
Naïve Bayesian Fusion and decision rationality analysis), this
analysis demonstrated the tool’s additional value in comparison
to the LR approaches. When the estimation of e.g. propensity
scores or adverse events is of concern, NBC can offer additional
predictive value compared to LR. In medicine, even one unnec-
essary faulty prediction is too much.
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OBJECTIVES: Due to joint risk factors, positive screening results
are often not only associated with mortality speciﬁc for the target
disease of screening, but also with an increased mortality due to
other causes. Most decision-analytic models do not consider this
association leading to potentially biased results. Our goal was to
develop a tool which helps to adjust for such joint mortality.
METHODS: We developed a function HR_other(HR_target)
characterizing the relationship between two mortality hazard
ratios (HRs). HR_target compares the mortality rate due to the
target disease among those at high risk versus low risk. HR_other
compares the respective mortality rates not directly related to
the target disease. We postulated several properties that must be
fulﬁlled by this function: 1) if the screening test result does not
explain the mortality (i.e. HR_other(HR_target) = 1) of the
target disease it also does not explain mortality due to other
causes; 2) the function HR_other(HR_target) is strictly increas-
ing in HR_target; 3) the relationship of HRs below 1 is derived
by taking the reciprocal values of the corresponding HRs above
1; 4) the function has an upper bound; 5) in the range of HRs
above 1, HR_target exceeds HR_other; and 6) the function
HR_other(HR_target) is continuously differentiable. We created
a function sufﬁcing all postulated properties and applied it in the
context of predictive coronary artery disease (CAD) screening.
We ﬁtted the function based of published HRs. Finally, we
applied this function to hypothetic screening methods, for which
only the HRs due to CAD were assumed to be known. The
generated HR_other can be used by decision-analysts for incor-
poration into their CAD decision-analytic models. CONCLU-
SION: We created a useful function that can be used for the
adjustment of differential non-target-disease related mortality
among risk groups in decision-analytic screening models. This
should result in more valid modeling results.
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OBJECTIVES: A comparative cost-effectiveness analysis of
generic versions of atorvastatin (atva) and simvastatin (simva)
with rosuvastatin (rosva) in patients with primary hypercholes-
terolemia in the RF. METHODS: This study compared two
brands of atva—Atoris (KRKA) and Tulip (LEK), and one of
simva—Vasilip (KRKA) with rosva—Crestor (AZ). Efﬁcacy data
in terms of percentage reduction in LDL cholesterol and propor-
tion of patients to European LDL cholesterol goals was taken
from the STELLAR trial. Price per pack data was obtained
in RUR from the wholesale Protek price-list (20.07.2006).
Exchange rate is 25.98 RUR per 1 USD and 34.75 RUR per 1
Euro. Meta-analysis of all available comparative clinical trials
has shown a relative effective dose of 1:3 for rosva compared
with atva and 1:8 for rosva vs simva. Hence cost and
efﬁcacy data for rosva 10 mg is compared with atva 30 mg
(20 mg + 10 mg) and with simva 80 mg (40 mg + 40 mg) in the
form cost per patient per year and cost per patient to European
LDL cholesterol goals. RESULTS: The cost per patient to LDL-C
goal for Crestor 10 mg is 17,914 RUR, for Atoris 30 mg, Tulip
30 mg and Vasilip 80 mg is 25,968; 25,372 and 27,692 RUR
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respectively. Within a budget of 10 million RUR the number of
patients at European LDL-C goal at 1 year is: 558 on Crestor,
361 on Vasilip, 385 on Atoris and 394 on Tulip. CONCLU-
SION: Based on the equi-effective dose of statins CRESTOR is
shown to be cost-effective compared to atorvastatin and simvas-
tatin even at low generic prices across all value metrics analysed.
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OBJECTIVES: The purpose of this study was to evaluate health
and economic beneﬁts, throughout the country, as the conse-
quence of the realization cardiovascular system diseases preven-
tion programme among the children and youth of school age in
Poland. METHODS: This was a health and an economic evalu-
ation using a simulation model based on 10,000 subjects. The
frequency of incidence of cardiovascular system diseases was
estimated using data from the Polish epidemiological trials pro-
grams and statistical yearbook. Costs of cardiovascular system
diseases treatment were derived from medical services catalogue
of The National Health Fund (NFZ). The effectiveness of pre-
ventive programmes was extracted from the INTERHEART
study and other published sources. RESULTS: Correctly con-
structed and conducted prevention programme of cardiovascular
system diseases among the children and youth of school age in
Poland could reduce about 70% lipid disorders, 50% obesity,
50% arterial hypertension, 8% heart attack, 5% the diabetes
mellitus type 2, and about 4% the cerebrovascular incident in
adult life of the beneﬁciaries. The indirect results of prevention
are the extending of life-span and the improvement of health
quality of individuals as well as their families, the improvement
of epidemiological situation and measurable ﬁnancial proﬁt
throughout the country because of dangerous and chronic health
complications prevention as well as lack of limitations of ability
to work. CONCLUSION: The cost of analysed preventive pro-
gramme of cardiovascular system diseases is about 15 times
smaller than health care costs of these diseases.
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OBJECTIVES: To perform a health technology assessment
(HTA) commissioned by the German Federal Ministry of Health
on coronary fractional ﬂow reserve (FFR) to guide the decision
on coronary stenting in patients with suspected mild coronary
artery disease (CAD). METHODS: We performed a systematic
literature search to identify clinical and economic studies on
FFR-guided strategies. A meta-analysis on the diagnostic value of
FFR and a review on economic evaluations were done. We devel-
oped a decision-analytic Coronary Artery Disease Outcome
Model (CADOM) for the German health care context. Patients
with angiographically suspected CAD without conﬁrmed diag-
nosis were modeled in subgroups for age and gender (basecase:
60-year old man). Model parameters were derived from German
databases and the published literature. We adopted the societal
perspective, used a life-time horizon, and discounted costs and
effects by 5% per year. RESULTS: We identiﬁed 10 diagnostic
accuracy studies, 1 multicenter randomized clinical trial (RCT)
for efﬁcacy, and 1 decision-analytic cost-effectiveness study (US
context). Pooled sensitivity and speciﬁcity of FFR was 81.7%
(95%CI: 77.0–85.7%) and 78.7% (95%CI: 74.3–82.7%),
respectively. Few studies used a sufﬁcient goldstandard. The RCT
investigated the efﬁcacy of a FFR-based treatment strategy and
showed advantages for patients in terms of major adverse cardiac
events and freedom from angina. The cost-effectiveness study
showed the FFR-based strategy being cost-saving in the US health
care system. Results from German CADOM indicated a gain in
(quality-adjusted) life-expectancy for the FFR-guided strategy
compared to universal coronary intervention in all patients. The
base-case discounted incremental cost-effectiveness ratio was
Euro 16,000 per QALY gained. Uni- and multivariate sensitivity
analyses showed robust results. CONCLUSION: This HTA sug-
gests that FFR-guided treatment results in clinical beneﬁts for
patients with suspected CAD and should be cost-effective in the
German context. FFR should be implemented in routine clinical
decision making in patients with suspected CAD.
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OBJECTIVES: The phenomena of response-shift has recently
entered the PRO literature and provided new insight how change
scores in PRO measures such as HRQL-instruments can be inter-
preted. Methods have been provided to investigate the 3 types of
response-shift: recalibration, reconceptualization and reprioriti-
zation. The aim of this study was to investigate to what extend
response-shift occurs in individualized vs. disease-speciﬁc
HRQL-instruments and how it can be captured. METHODS: In
a prospective longitudinal study 100 patients with angiographi-
cally documented coronary artery disease were approached at 2
time points (hospital-baseline and 6 month-follow-up) with an
individualized QoL-instrument (Schedule for the Evaluation of
Individualized Quality of Life; SEIQOL) and a disease-speciﬁc
HRQL-instrument (MacNew Heart Disease Quality of Life
Questionnaire; MacNew). The SEIQoL is constructed allowing
capturing two aspects of response-shift: reconceptualization
(cues) and reprioritization (weights). In addition the “Then-Test”
was applied to the MacNew at 6 month-follow-up to capture
recalibration. RESULTS: Informed consent was given by 64
patients (61+/-7.5 years, 28.1% female, main symptom: 71.9%
angina) and all patients were treated with percutaneous coronary
interventions. 71.9% returned the six-month follow-up. Indi-
vidualized QoL (SEIQoL-Index) did not improve over the 6
month-period (t0: 65.8+/-25.5; t1: 67.8+/-20.5, p = ns), in addi-
tion 25% of the participants showed response-shift effects of
reconceptualization in at least one cue of the SEIQoL. No sig-
niﬁcant change in SEIQoL cue-weights occurred. Disease-speciﬁc
HRQL scores changed signiﬁcantly over time (t0: 4.7+/-1.2, t1:
5.3+/-1.1, p = 0.004); and no recalibration occurred (t0-then-
test: 4.6+/-1.4, p = 0.418). CONCLUSION: This prospective
study investigating the effects of percutaneous coronary interven-
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